Publications by authors named "J S Blachly"
Hairy cell leukemia is an uncommon B-cell malignancy with excellent response to purine analogs and to targeted therapies such as ibrutinib and vemurafenib. However, purine analogs are known to be highly immunosuppressive and the infection burden in this patient population with current therapies is unknown. We therefore conducted a retrospective cohort study following 149 patients.
View Article and Find Full Text PDFGenomic profiles and prognostic biomarkers in patients with acute myeloid leukemia (AML) from ancestry-diverse populations are underexplored. We analyzed the exomes and transcriptomes of 100 patients with AML with genomically confirmed African ancestry (Black; Alliance) and compared their somatic mutation frequencies with those of 323 self-reported white patients with AML, 55% of whom had genomically confirmed European ancestry (white; BeatAML). Here we find that 73% of 162 gene mutations recurrent in Black patients, including a hitherto unreported PHIP alteration detected in 7% of patients, were found in one white patient or not detected.
View Article and Find Full Text PDFArticle Synopsis
- AZD5991 is a drug being tested for safety and effectiveness in patients with relapsed or refractory blood cancers, both by itself and alongside another drug called venetoclax.
- The clinical trial involved 61 patients receiving varying doses of AZD5991, while 17 patients took it in combination with venetoclax, focusing on determining safe dosage levels and any anti-cancer effects.
- Results showed significant side effects such as diarrhea and nausea, with a low overall response rate to treatment, despite a few patients achieving partial or complete remission.
Purpose: Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with -rearranged () acute leukemia. Here, we evaluated the activity of revumenib in individuals with relapsed/refractory (R/R) acute leukemia.
Methods: AUGMENT-101 is a phase I/II, open-label, dose-escalation and expansion study of revumenib conducted across 22 clinical sites in five countries (ClinicalTrials.